TrovaGene Inc. (TROV)

0.30
0.01 3.20
NASDAQ : Health Technology
Prev Close 0.31
Open 0.31
Day Low/High 0.28 / 0.32
52 Wk Low/High 0.23 / 1.63
Volume 1.80M
Avg Volume 2.03M
Exchange NASDAQ
Shares Outstanding 55.29M
Market Cap 17.75M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Trovagene Announces Activation Of Two Additional Clinical Trial Sites To Conduct Its Phase 1b/2 Study Of PCM-075 In Patients With AML

Trovagene Announces Activation Of Two Additional Clinical Trial Sites To Conduct Its Phase 1b/2 Study Of PCM-075 In Patients With AML

Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in Acute Myeloid Leukemia (AML)

Trovagene Presents Data Showing Synergy Of PCM-075 In Combination With Zytiga® In Castration-Resistant Prostate Cancer Model At 2018 Genitourinary Cancers Symposium

Trovagene Presents Data Showing Synergy Of PCM-075 In Combination With Zytiga® In Castration-Resistant Prostate Cancer Model At 2018 Genitourinary Cancers Symposium

Targeted treatment with highly-selective Polo-like Kinase 1 inhibitor PCM-075 in combination with Zytiga® (abiraterone acetate) may represent a new treatment option in CRPC

Trovagene Announces Initiation Of UNITE Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Trovagene Announces Initiation Of UNITE Phase 2 Clinical Trial Of PCM-075 In Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PCM-075, Trovagene's highly-selective Polo-like Kinase 1 (PLK1) inhibitor may extend patient response to therapy when used in combination with Zytiga® (abiraterone) in mCRPC

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Trovagene Announces Activation Of Second Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Activation of second trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of PCM-075 In Combination With Zytiga® For Metastatic Castration-Resistant Prostate Cancer

Trovagene Submits Protocol To FDA For Phase 2 Clinical Trial Of PCM-075 In Combination With Zytiga® For Metastatic Castration-Resistant Prostate Cancer

PCM-075, Trovagene's Polo-like Kinase 1 (PLK1) inhibitor enhances activity of abiraterone in mCRPC tumor cells and may represent a novel combination treatment option in mCRPC

Trovagene Presents Data Showing Sensitivity Of Triple Negative Breast Cancer (TNBC) Cell Lines To PCM-075 And Synergy With Zytiga® At San Antonio Breast Cancer Symposium (SABCS)

Trovagene Presents Data Showing Sensitivity Of Triple Negative Breast Cancer (TNBC) Cell Lines To PCM-075 And Synergy With Zytiga® At San Antonio Breast Cancer Symposium (SABCS)

Targeted treatment with highly selective Polo-like Kinase 1 inhibitor, PCM-075, may represent a new option in TNBC, particularly in combination with other abiraterone acetate

Trovagene Announces Activation Of First Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Trovagene Announces Activation Of First Clinical Trial Site In Phase 1b/2 Acute Myeloid Leukemia (AML) Trial For PCM-075

Activation of first trial site for Phase 1b/2 clinical trial of PCM-075, in combination with standard-of care, to evaluate dose and scheduling, and preliminary anti-leukemic activity

Short Interest Expands By 14.2% For TROV

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 442,930 share increase in total short interest for TrovaGene Inc , to 3,567,833, an increase of 14.17% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Short Interest Moves 16.3% Higher For TROV

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 460,990 share increase in total short interest for TrovaGene Inc , to 3,292,918, an increase of 16.28% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TrovaGene (TROV) Is Today's Strong On High Volume Stock

TrovaGene (TROV) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified TrovaGene (TROV) as a strong on high relative volume candidate

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Trovagene, Inc. - TROV

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Trovagene, Inc.

Short Interest Jumps 17.6% For TROV

Short Interest Jumps 17.6% For TROV

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 697,508 share increase in total short interest for TrovaGene Inc , to 4,657,297, an increase of 17.61% since 01/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Here’s Why TrovaGene (TROV) Stock is Soaring Today

Here’s Why TrovaGene (TROV) Stock is Soaring Today

TrovaGene (TROV) stock is spiking on Monday afternoon as the company enters an agreement with FedMed for access to cancer monitoring tests and services.

TrovaGene (TROV) Is Weak On High Volume Today

TrovaGene (TROV) Is Weak On High Volume Today

Trade-Ideas LLC identified TrovaGene (TROV) as a weak on high relative volume candidate

Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership

Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership

Trovagene (TROV) stock is climbing on heavy trading volume on Thursday after the company announced a partnership with America's Choice Provider Network.

Oversold Conditions For TrovaGene (TROV)

Oversold Conditions For TrovaGene (TROV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TROV: Insiders vs. Shorts

TROV: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 11/30/2015 settlement date, and TrovaGene Inc is one of the most shorted stocks of the Russell 3000, based on 8.86 "days to cover" versus the median component at 6.38. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Interesting TROV Put And Call Options For July 2016

Interesting TROV Put And Call Options For July 2016

Investors in TrovaGene Inc saw new options begin trading this week, for the July 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

First Week of TROV December 18th Options Trading

First Week of TROV December 18th Options Trading

Investors in TrovaGene Inc saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TROV options chain for the new December 18th contracts and identified the following call contract of particular interest.

First Week Of April 2016 Options Trading For TrovaGene (TROV)

First Week Of April 2016 Options Trading For TrovaGene (TROV)

Investors in TrovaGene Inc saw new options begin trading this week, for the April 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Oversold Conditions For TrovaGene (TROV)

Oversold Conditions For TrovaGene (TROV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TrovaGene Enters Oversold Territory (TROV)

TrovaGene Enters Oversold Territory (TROV)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D- (Sell)